(NYSE: OGN) Organon & Co's forecast annual revenue growth rate of -0.17% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 7.27%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.85%.
Organon & Co's revenue in 2025 is $6,294,000,000.On average, 3 Wall Street analysts forecast OGN's revenue for 2025 to be $1,623,293,035,843, with the lowest OGN revenue forecast at $1,614,675,492,354, and the highest OGN revenue forecast at $1,634,585,527,220. On average, 3 Wall Street analysts forecast OGN's revenue for 2026 to be $1,625,756,379,496, with the lowest OGN revenue forecast at $1,594,830,446,505, and the highest OGN revenue forecast at $1,651,259,109,100.
In 2027, OGN is forecast to generate $1,642,861,488,441 in revenue, with the lowest revenue forecast at $1,598,001,910,474 and the highest revenue forecast at $1,685,136,583,231.